Therefore, targeting TrkB may reduce the malignancy of NB with dysregulated TrkB, which can be achieved by the TrkB inhibitors GNF-4256 (ref. 287) or AZD6918 (ref. 288), which have shown promising results alone and in combination in a xenograft mouse model. The gene discussed is NTRK2; the disease is neuroblastoma.